Anaphylactic shock or anaphylaxis is a severe and sometimes life-threatening immune system reaction to an antigen that a person has been previously exposed to. The reaction may include itchy skin, edema, collapsed blood vessels, fainting, difficulty in breathing, and death.
Pfizer Inc. announced today that the European Commission has granted conditional marketing authorization for BOSULIF (bosutinib) in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).
Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.
PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
Researchers have learned how a man-made molecule destroys complexes that induce allergic responses - a discovery that could lead to the development of highly potent, rapidly acting interventions for a host of acute allergic reactions.
Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Allergies, or hypersensitivities of the immune system, are more common than ever before. According to the Asthma and Allergies Foundation of America, one in five Americans suffers from an allergy - from milder forms like hay fever to more severe instances, like peanut allergies which can lead to anaphylactic shock.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
Food allergies pose a serious and growing problem in the West. Many foods can lead to allergic reactions and this situation is further complicated by so-called cross-reactions, whereby an allergy to one particular food can trigger allergic reactions to another food. There are no treatments available for food allergies, but the establishment of two mouse models can be used to develop and test new forms of treatment, for example vaccines.
Yale researchers suggested Wednesday that allergies may be an outgrowth of the protective mechanism of the body to protect itself from noxious substances in the environment.
Research suggests that most victims of home-bred midges, mosquitoes, flies, bedbugs and fleas will get better without any treatment at all. The review in the Drug and Therapeutics Bulletin (DTB), which offers impartial advice to doctors, admits that getting bitten may be horribly uncomfortable but there is little evidence that over-the-counter remedies work. Putting a cold compress to relieve pain and swelling could be a better option say researchers. Medical help should clearly be sought if serious symptoms, such as infections or anaphylactic shock, developed the DTB added.
Researchers at CSIRO and experts at Geelong's Deakin University have found a way to “switch off” four egg allergens. These modified eggs could produce chickens that lay hypoallergenic eggs but the genes and DNA of the chicken would remain unaltered.
Fruits and veggies, air filters, spring breezes, procrastination and self-medication - each can delay relief from a stuffy nose, sneezing, sniffling or other symptoms if you're one of the more than 35 million Americans who suffer from seasonal allergies.
Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.
At a time when research funding is hard to come by, a University of Central Florida and University of Florida partnership has landed almost $5.5 million in National Institutes of Health highly competitive grants for hemophilia research.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.